Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: Results of the SNOWDROP trial

Menopause

Volumn 21, Issue 6, 2014, Pages 633-640

  Simon, James A ^a   Kingsberg, Sheryl A ^b   Shumel, Brad ^c   Hanes, Vladimir ^d   Garcia, Miguel ^c   Sand, Michael ^c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Female sexual dysfunction; Flibanserin; Hypoactive sexual desire disorder; Low desire.; Menopausal

Indexed keywords

FLIBANSERIN; PLACEBO; BENZIMIDAZOLE DERIVATIVE; SEROTONIN AGONIST;

ADULT; ARTICLE; BEDTIME DOSAGE; CONTROLLED STUDY; DISTRESS SYNDROME; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEMALE SEXUAL FUNCTION INDEX; HEADACHE; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEXUAL SATISFACTION; SOMNOLENCE; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; MIDDLE AGED; QUESTIONNAIRE; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SEXUALITY;

ADULT; AGED; BENZIMIDAZOLES; DISORDERS OF EXCESSIVE SOMNOLENCE; DIZZINESS; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; MIDDLE AGED; NAUSEA; POSTMENOPAUSE; QUESTIONNAIRES; SEROTONIN RECEPTOR AGONISTS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SEXUALITY;

EID: 84901615796     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000134     Document Type: Article

References (42)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, DC: American Psychiatric Press, 2000:1-943.
2. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008;112:970-978.
3. Laumann EO, Waite LJ. Sexual dysfunction among older adults: prevalence and risk factors from a nationally representative U.S. probability sample of men and women 57-85 years of age. J Sex Med 2008;5: 2300-2311.
4. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med 2007;357:762-774.
5. Hayes RD, Dennerstein L, Bennett CM, Fairley CK. What is the Btrue[ prevalence of female sexual dysfunctions and does the way we assess these conditions have an impact? J Sex Med 2008;5:777-787.
6. West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med 2008;168:1441-1449.
7. Rosen RC, Shifren JL, Monz BU, Odom DM, Russo PA, Johannes CB. Correlates of sexually related personal distress in women with low sexual desire. J Sex Med 2009;6:1549-1560.
8. Simon JA. Low sexual desireVis it all in her head? Pathophysiology, diagnosis, and treatment of hypoactive sexual desire disorder. Postgrad Med 2010;122:128-136.
9. Pfaus JG. Pathways of sexual desire. J Sex Med 2009;6:1506-1533.
10. Bancroft J, Graham CA, Janssen E, Sanders SA. The dual control model: current status and future directions. J Sex Res 2009;46:121-142.
11. Clayton AH. The pathophysiology of hypoactive sexual desire disorder in women. Int J Gynaecol Obstet 2010;110:7-11.
12. Panay N, Al-Azzawi F, Bouchard C, et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric 2010;13:121-131.
13. Davis SR, Braunstein GD. Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2012;9:1134-1148.
14. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-688.
15. Basson R, Brotto LA, Petkau AJ, Labrie F. Role of androgens in women's sexual dysfunction. Menopause 2010;17:962-971.
16. European Medicines Agency (EMA). Intrinsa summary of product characteristics. Available at: http://www.ema.europa.eu/ema/index.jsp?curl= pages/medicines/human/medicines/000634/human-med-000845.jsp&murl=menus/ medicines/medicines.jsp&mid=WC0b01ac058001d124. Accessed February 27, 2012.
17. US Food andDrugAdministration. Draft guidance for industryVfemale sexual dysfunction: clinical development of drug products for treatment. Available at: http://www.fda.gov/ScienceResearch/SpecialTopics/WomensHealthResearch/ucm133202. htm. Accessed February 27, 2012.
18. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S. Pharmacology of flibanserin. CNS Drug Rev 2002;8:117-142.
19. Allers KA, Dremencov E, Ceci A, et al. Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: a microdialysis study. J Sex Med 2010;7:1757-1767.
20. Stahl SM, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med 2011;8:15-27.
21. Marazziti D, Palego L, Giromella A, et al. Region-dependent effects of flibanserin and buspirone on adenylyl cyclase activity in the human brain. Int J Neuropsychopharmacol 2002;5:131-140.
22. DeRogatis LR, Komer L, Katz M, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET study. J Sex Med 2012;9:1074-1085.
23. Katz M, DeRogatis LR, Ackerman R, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med 2013;10:1807-1815.
24. Thorp J, Simon J, Dattani D, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med 2012;9:793-804.
25. Jayne C, Simon JA, Taylor LV, Kimura T, Lesko LM. Open-label extension study of flibanserin in women with hypoactive sexual desire disorder. J Sex Med 2012;9:3180-3188.
26. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191-208.
27. DeRogatis LR, Clayton A, Lewis-D'Agostino D, Wunderlich G, Fu Y. Validation of the Female Sexual Distress ScaleVRevised for assessing distress in women with hypoactive sexual desire disorder. J SexMed 2008;5:357-364.
28. Clayton AH, Goldmeier D, Nappi RE,Wunderlich G, Lewis-D'Agostino DJ, Pyke R. Validation of the Sexual Interest and Desire InventoryVFemale in hypoactive sexual desire disorder. J SexMed 2010;7:3918-3928.
29. Beck AT, Steer RA, Brown GK. Beck Depression Inventory: Manual, 2nd ed. San Antonio, TX: The Psychological Corporation, 1996:1-38.
30. Posner K. State of the science: measurement of suicidal adverse events and the Columbia Suicide Severity Rating Scale. Paper presented at: 47th New Clinical Drugs Evaluation Unit (NCDEU) Annual Meeting; June 11-14, 2007; Boca Raton, FL.
31. DeRogatis LR, Pyke R, McCormack J, Hunter A, Harding G. Does the Female Sexual Distress ScaleVRevised cover the feelings of women with HSDD? J Sex Med 2011;8:2810-2815.
32. Meston CM. Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. J Sex Marital Ther 2003;29:39-46.
33. Revicki DA, Margolis MK, Bush EN, DeRogatis LR, Hanes V. Content validity of the Female Sexual Function Index (FSFI) in pre-and postmenopausal women with hypoactive sexual desire disorder. J Sex Med 2011;8:2237-2245.
34. Clayton AH, Dennerstein L, Fisher WA, Kingsberg SA, Perelman MA, Pyke RE. Standards for clinical trials in sexual dysfunction in women: research designs and outcomes assessment. J Sex Med 2010;7:541-560.
35. Rosen RC, Maserejian NN, Connor MK, Krychman ML, Brown CS, Goldstein I. Characteristics of premenopausal and postmenopausal women with acquired, generalized hypoactive sexual desire disorder: the Hypoactive Sexual Desire Disorder Registry for women. Menopause 2012;19:396-405.
36. Goldfischer ER, Breaux J, Katz M, et al. Continued efficacy and safety of flibanserin in premenopausal women with hypoactive sexual desire disorder (HSDD): results from a randomized withdrawal trial. J Sex Med 2011;8:3160-3172.
37. Watanabe N, Omori IM, Nakagawa A, et al. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acutephase treatment of adults with depression: systematic review and metaanalysis. CNS Drugs 2010;24:35-53.
38. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000;355:911-918.
39. Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005;165:1582-1589.
40. Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90: 5226-5233.
41. Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005;105(PART. 1):944-952.
42. Johannes C, Clayton AH, Odom DM, et al. Distressing sexual problems in United States women revisted: prevalence after accounting for depression. J Clin Psychiatry 2009;70:1698-1706.